Medication info
Linarutinduo 2.5/500 mg (Linagliptin, Metformin)

Linarutinduo 2.5/500 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceuticals Co., Ltd.
Appearance
Yellow, double-convex, oval film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401059 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dosage should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dosage of this medication is 2.5/500 mg, 1 tablet twice daily. The dosage may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should take an initial dosage equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dosage similar to the patient's existing metformin dosage. When this medication is administered in combination with insulin, a reduction in the insulin dosage may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Administration). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Ingredients

Manufacturer
Shinpoong Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes who are taking linagliptin and metformin together. When used alongside dietary and exercise therapy, it enhances efficacy for more stable blood sugar management. This aids patients in managing their diabetes more effectively.

How to take

Adult dose

The dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dosage should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dosage of this medication is 2.5/500 mg, 1 tablet twice daily. The dosage may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should take an initial dosage equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dosage similar to the patient's existing metformin dosage. When this medication is administered in combination with insulin, a reduction in the insulin dosage may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Administration). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Precautions

This medication contains two components, linagliptin and metformin, that help control blood sugar. Before taking this medication, caution is advised due to the rare but serious risk of lactic acidosis, which may be heightened in cases of impaired kidney function or pre-existing issues with the heart or liver. This medication should not be used in specific patient situations. For instance, patients with allergies to linagliptin or metformin, those with type 1 diabetes, severely impaired kidney function, acute infections, or severe dehydration, as well as pregnant or nursing women, should avoid taking it. Additionally, this medication should be used cautiously and with regular monitoring of kidney function, especially in older adults or those with mildly impaired kidney function. If this medication is used alongside sulfonylureas or insulin, the risk of hypoglycemia may increase, necessitating careful monitoring of blood sugar levels. If patients experience persistent and severe abdominal pain, sudden skin rashes, or blisters while on this medication, they should consult a doctor immediately, as these may indicate serious side effects such as pancreatitis or bullous pemphigoid. The metformin component may lower vitamin B12 levels, so it’s advisable to check for vitamin B12 deficiency with long-term use. Taking this medication with alcohol may increase the risk of lactic acidosis, so it is safest to avoid alcohol consumption. When undergoing radiological examinations using iodinated contrast agents, this medication should be temporarily discontinued before and after the procedure and can be resumed only once kidney function is stabilized. If surgery is scheduled, the medication should be stopped 48 hours prior and can only be resumed after confirming that kidney function has returned to normal post-surgery. Since kidney impairment is common in older adults, regular monitoring of kidney function and dosage adjustments may be necessary when using this medication. Women who are pregnant or planning to become pregnant should avoid taking this medication and should consider alternative methods for blood sugar control. The safety and efficacy of this medication have not been established in children and adolescents (under 10 years), thus it is not recommended for this age group. In cases of overdose, gastrointestinal disturbances or lactic acidosis may occur, necessitating immediate medical treatment, possibly including hemodialysis. This medication should be stored in a tightly closed container to avoid moisture and kept out of reach of children; transferring to another container is not recommended.

Side effects

Lactic acidosis, hypoglycemia, dysgeusia, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular dermatitis, severe joint pain accompanied by disability, rhabdomyolysis, elevated lipase, elevated amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, cheilitis, stomatitis, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, constipation, epigastric pain, dyspepsia, rectal bleeding, dental caries, enteritis, gastritis, stomatitis, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, erectile dysfunction, goiter, kidney transplant failure, anemia, headache, sensory disturbances, postherpetic neuralgia, hemiparesis, syncope, drowsiness, chest discomfort, asthenia, pain, epistaxis, oropharyngeal pain, voice disorders, nasal bleeding, male-pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, affective disorder, insomnia, depression, hypertension, benign prostatic hyperplasia, confusional state, nocturia, pruritus, osteoarthritis, limb pain, dizziness, increased triglycerides in blood, decreased hemoglobin, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, elevated ALT, elevated AST, elevated blood glucose, increased creatinine in blood, fever, facial swelling, hyperthermia, back pain, flank pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, vitreous hemorrhage, vocal cord polyp, ligament sprain, flank pain, myelodysplastic syndrome, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, rhinitis, fever, ligament sprain, flank pain, myelodysplastic syndrome, voice disorders, dyspnea, nasal bleeding, hearing loss, benign, malignant, and unspecified neoplasms (including cysts and polyps)

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is advisable to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, double-convex, oval film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.